{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:27:36Z","timestamp":1792542456078,"version":"4.5.0"},"reference-count":73,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In an effort to discover potent anticancer agents, 2-thiouracil-5-sulfonamides derivatives were designed and synthesized. The cytotoxic activity of all synthesized compounds was investigated against four human cancer cell lines viz A-2780 (ovarian), HT-29 (colon), MCF-7 (breast), and HepG2 (liver). Compounds 6b,d\u2013g, and 7b showed promising anticancer activity and significant inhibition of CDK2A. Moreover, they were all safe when tested on WI38 normal cells with high selectivity index for cancer cells. Flow cytometric analysis for the most active compound 6e displayed induction of cell growth arrest at G1\/S phase (A-2780 cells), S phase (HT-29 and MCF-7 cells), and G2\/M phase (HepG2 cells) and stimulated the apoptotic death of all cancer cells. Moreover, 6e was able to cause cycle arrest indirectly through enhanced expression of cell cycle inhibitors p21 and p27. Finally, molecular docking of compound 6e endorsed its proper binding to CDK2A, which clarifies its potent anticancer activity.<\/jats:p>","DOI":"10.3390\/ijms222111957","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T09:11:32Z","timestamp":1636017092000},"page":"11957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Synthesis of Novel 2-Thiouracil-5-Sulfonamide Derivatives as Potent Inducers of Cell Cycle Arrest and CDK2A Inhibition Supported by Molecular Docking"],"prefix":"10.3390","volume":"22","author":[{"given":"Samar S.","family":"Fatahala","sequence":"first","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira I.","family":"Sayed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6095-1081","authenticated-orcid":false,"given":"Shahenda","family":"Mahgoub","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Taha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-I kotb","family":"El-Sayed","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed F.","family":"El-Shehry","sequence":"additional","affiliation":[{"name":"Pesticide Chemistry Department, National Research Centre, Dokki 12622, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Awad","sequence":"additional","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania H.","family":"Abd El-Hameed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1016\/j.bmcl.2010.06.121","article-title":"Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells","volume":"20","author":"Zheng","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2014.06.027","article-title":"Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest","volume":"83","author":"Fares","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/cbdd.13334","article-title":"Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation","volume":"92","author":"Vekariya","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","article-title":"Identification and Characterization of an Irreversible Inhibitor of CDK2","volume":"22","author":"Anscombe","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/1878-0261.12148","article-title":"Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor","volume":"12","author":"Whittaker","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","article-title":"2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells","volume":"113","author":"Bauer","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1016\/S0021-9258(19)52479-6","article-title":"5-Fluoro-2\u2032-deoxyuridine incorporation in L1210 DNA","volume":"256","author":"Kufe","year":"1981","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/02841868709091751","article-title":"Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo","volume":"26","author":"Lewin","year":"1987","journal-title":"Acta Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1349-7006.1999.tb00800.x","article-title":"Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line","volume":"90","author":"Takeda","year":"1999","journal-title":"Jap. J. Cancer Res."},{"key":"ref_13","first-page":"2091","article-title":"Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model","volume":"18","author":"Gu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-Fluorouracil: Mechanisms of resistance and reversal strategies","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"},{"key":"ref_15","first-page":"199","article-title":"In silico methods reconfirm CDK2 as a potential molecular target of 5-fluorouracil","volume":"53","author":"Yata","year":"2016","journal-title":"Indian J. Biochem. Biophys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/14756366.2021.1890726","article-title":"Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy","volume":"36","author":"Alsfouk","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/jm049355+","article-title":"Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4","volume":"48","author":"VanderWel","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejmech.2013.07.031","article-title":"6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity","volume":"68","author":"Boschi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.bmcl.2005.01.079","article-title":"Structure\u2013activity relationships for 2-anilino-6-phenylpyrido[2, 3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1","volume":"15","author":"Palmer","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-06-0355","article-title":"In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials","volume":"5","author":"DePinto","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.RA118.004673","article-title":"Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy","volume":"293","author":"Xia","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.2174\/138161212800672804","article-title":"Cyclin-dependent kinase inhibitors inspired by roscovitine: Purine bioisosteres","volume":"18","author":"Jorda","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E204","DOI":"10.1208\/aapsj080125","article-title":"Selectivity and potency of cyclin-dependent kinase inhibitors","volume":"8","author":"Sridhar","year":"2006","journal-title":"AAPS J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1016\/j.bmcl.2007.04.110","article-title":"Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping","volume":"17","author":"Richardson","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"137329","DOI":"10.1016\/j.cplett.2020.137329","article-title":"Identifying hot spots of inhibitor-CDK2 bindings by computational alanine scanning","volume":"747","author":"Zhao","year":"2020","journal-title":"Chem. Phys. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"Hydbring","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2019.01.008","article-title":"Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity","volume":"86","author":"Ali","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/mol.115.099325","article-title":"Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics","volume":"88","author":"Law","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: A changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejmech.2017.07.067","article-title":"Recent advances on CDK inhibitors: An insight by means of in silico methods","volume":"142","author":"Tutone","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Madia, V.N., Nicolai, A., Messore, A., De Leo, A., Ialongo, D., Tudino, V., Saccoliti, F., De Vita, D., Scipione, L., and Artico, M. (2021). Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents. Molecules, 26.","DOI":"10.3390\/molecules26030771"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"113309","DOI":"10.1016\/j.ejmech.2021.113309","article-title":"Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure","volume":"216","author":"Jansa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","first-page":"795","article-title":"The potential antiviral activity of a novel pyrimidine derivative against Herpes Simplex Virus type-1 (HSV-1)","volume":"11","author":"Hassan","year":"2020","journal-title":"Rev. Pharm."},{"key":"ref_39","unstructured":"Walker, R.T., Jones, A.S., Rahim, S.G., Serafinowski, P., and De Clercq, E. (1981). The synthesis and properties of some 5-substituted uracil derivatives. Nucleic Acids Symp. Ser., 21\u201324."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10426509508027936","article-title":"The synthesis and chlorosulfonation of some diarylidene and heteroarylidene ketones with varying alicyclic ring size","volume":"107","author":"Cremlyn","year":"1995","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"key":"ref_41","first-page":"202784","article-title":"Significance and biological importance of pyrimidine in the microbial world","volume":"2014","author":"Sharma","year":"2014","journal-title":"Int. J. Med. Chem."},{"key":"ref_42","first-page":"102","article-title":"Design, synthesis, molecular docking of new thiopyrimidine-5-carbonitrile derivatives and their cytotoxic activity against HepG2 cell line","volume":"4","author":"Eweas","year":"2014","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1021\/acsomega.8b00361","article-title":"O-Regioselective Synthesis with the Silver Salt Method","volume":"3","author":"Wang","year":"2018","journal-title":"ACS Omega"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3390\/molecules13102340","article-title":"Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems","volume":"13","author":"Arias","year":"2008","journal-title":"Molecules"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_46","first-page":"4209","article-title":"Regulation of RNA-and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells","volume":"40","author":"Maybaum","year":"1980","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"H\u00fcbbers, A., Hennings, J., Lambertz, D., Haas, U., Trautwein, C., Nevzorova, Y.A., Sonntag, R., and Liedtke, C. (2020). Pharmacological Inhibition of Cyclin-Dependent Kinases Triggers Anti-Fibrotic Effects in Hepatic Stellate Cells In Vitro. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093267"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Schloer, S., Pajonczyk, D., and Rescher, U. (2018). Annexins in Translational Research: Hidden Treasures to Be Found. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201805.0378.v1"},{"key":"ref_49","first-page":"e2597","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"ref_50","first-page":"953","article-title":"Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry","volume":"2016","author":"Crowley","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/B978-0-12-385493-3.00004-8","article-title":"Apoptosis and beyond: Cytometry in studies of programmed cell death","volume":"103","author":"Wlodkowic","year":"2011","journal-title":"Methods Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-016-0433-9","article-title":"Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword","volume":"35","author":"Visconti","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-04-3995","article-title":"Lost in transcription: p21 repression, mechanisms, and consequences","volume":"65","author":"Gartel","year":"2005","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/bcr277","article-title":"The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer","volume":"3","author":"Chiarle","year":"2001","journal-title":"Breast Cancer Res."},{"key":"ref_55","unstructured":"Sluyser, M. (2005). Application of Apoptosis to Cancer Treatment, Springer Science & Business Media."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.bjc.6603448","article-title":"Upregulation of p27 and its inhibition of CDK2\/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21","volume":"95","author":"He","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1039\/c3mb70186g","article-title":"An in silico exploration of the interaction mechanism of pyrazolo [1, 5-a] pyrimidine type CDK2 inhibitors","volume":"9","author":"Li","year":"2013","journal-title":"Mol. Biosyst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/prot.22136","article-title":"A novel binding pocket of cyclin-dependent kinase 2","volume":"74","author":"Chen","year":"2009","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.3390\/ijms16059314","article-title":"Insights on structural characteristics and ligand binding mechanisms of CDK2","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14756366.2019.1693702","article-title":"Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model","volume":"35","author":"Liang","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF02976623","article-title":"Synthesis of new 2-thiouracil-5-sulfonamide derivatives with biological activity","volume":"25","author":"Fathalla","year":"2002","journal-title":"Arch. Pharm. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40242-015-4445-3","article-title":"Synthesis and biological evaluation of novel uracil and 5-fluorouracil-1-yl acetic acid-colchicine conjugate","volume":"31","author":"Shen","year":"2015","journal-title":"Chem. Res. Chin. Univ."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.bmcl.2016.02.013","article-title":"Synthesis of hybrid 4-deoxypodophyllotoxin-5-fluorouracil compounds that inhibit cellular migration and induce cell cycle arrest","volume":"26","author":"Guan","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13177","DOI":"10.3390\/molecules190913177","article-title":"Design and synthesis of new cholesterol-conjugated 5-Fluorouracil: A novel potential delivery system for cancer treatment","volume":"19","author":"Radwan","year":"2014","journal-title":"Molecules"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1016\/j.bmc.2011.09.036","article-title":"Synthesis and in vitro cytotoxic activity of novel pyrazolo[3,4-d]pyrimidines and related pyrazole hydrazones toward breast adenocarcinoma MCF-7 cell line","volume":"19","author":"Hassan","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.bmc.2009.01.037","article-title":"Synthesis of novel substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells","volume":"17","author":"Zheng","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1016\/j.bmcl.2009.05.126","article-title":"Synthesis and antitumor activity of substituted triazolo[4,3-a]pyrimidin-6-sulfonamide with an incorporated thiazolidinone moiety","volume":"19","author":"Hafez","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13880200600592301","article-title":"Selective anticancer activity of pure licamichauxiioic-B acid in cultured cell lines","volume":"44","author":"Badisa","year":"2006","journal-title":"Pharm. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41418-018-0160-1","article-title":"The AHR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis","volume":"25","author":"Pollet","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3892\/ijmm.2014.1795","article-title":"Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: Underlying molecular mechanisms","volume":"34","author":"Abaza","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"ref_72","first-page":"29","article-title":"Synthesis of novel pyrrolopyrimidine derivatives as CDK2 inhibitors","volume":"9","author":"Sayed","year":"2018","journal-title":"Pharmacophore"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1107\/S2059798316000954","article-title":"Automated harvesting and processing of protein crystals through laser photoablation","volume":"72","author":"Zander","year":"2016","journal-title":"Acta Crystallogr. D Struct. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:25:51Z","timestamp":1760167551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":73,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111957"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111957","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}